Project 2: Bromodomains as Epigenetic Modulators of Endocrine Responsiveness in ER+ Breast Cancer

项目 2:溴结构域作为 ER 乳腺癌内分泌反应性的表观遗传调节剂

基本信息

项目摘要

PROJECT 2: SUMMARY Breast cancer (BCa) ranks among the leading causes of cancer death in women worldwide. Estrogen Receptor alpha positive tumors (ER+) are the most common subtype of BCa (~70% of all cases), and are effectively treated with anti-endocrine therapies that target ER. However, relapse frequently occurs resulting in the development of endocrine therapy resistance (ETR) and late stage metastatic disease. Substantial evidence indicates that transcriptional plasticity is a prominent feature of ETR, which provides subpopulations of cancer cells with the ability to adapt to therapeutic challenges. However, the molecular regulatory networks that govern anti-estrogen responsiveness in BCa cells remain poorly understood. It is well established that histone lysine acetylation patterns establish cell type enhancer programs to direct BCa phenotypes. Bromodomain (BRD) chromatin reader proteins are the primary readers of histone lysine acetylation. Despite being recognized as key epigenetic mechanisms in cancer and emerging `druggable targets', there are large gaps in our understanding of the functional relationships that exist between histone acetyllysine and BRDs. In addition, little is known regarding the role of BRDs in BCa anti-estrogen responses. We have previously characterized the altered epigenomic profiles in cell models of BCa and ETR. Our published results provide support that epigenome-wide reprogramming of estrogen-responsive elements is linked to endocrine sensitivity and the acquisition of ETR. Through an integrated and systematic set of specific aims, we will test the hypothesis that BRDs mediate endocrine responsiveness in BCa. This project will specifically focus on three main aspects that might have the potential for improved targeted therapies: The identification of specific bromodomain-containing proteins that can be targeted to enhance cellular responses to tamoxifen in cancer treatment, determination of the contributions of BRD-containing proteins to transcriptional plasticity during the early and late phases of ET, and characterization of the epigenetic landscape of recurrent metastatic ER+ breast cancer to link the global acetylome with histone binding activity of BRDs. Overall, this work will contribute to our understanding of BCa epigenetic mechanisms and will facilitate the discovery of new biomarkers for endocrine responsiveness and the development of new modalities for therapeutic intervention.
项目2:概要 乳腺癌(BCa)是全球女性癌症死亡的主要原因之一。雌激素受体 α阳性肿瘤(ER+)是BCa最常见的亚型(约占所有病例的70%), 以雌激素受体为靶点的抗内分泌治疗。然而,复发经常发生,导致 内分泌治疗抗性(ETR)和晚期转移性疾病的发展。大量证据 表明转录可塑性是ETR的一个突出特征,它提供了癌症的亚群, 有能力适应治疗挑战的细胞。然而,控制这些细胞的分子调控网络 BCa细胞中的抗雌激素反应性仍然知之甚少。已经确定组蛋白赖氨酸 乙酰化模式建立细胞类型增强子程序以指导BCa表型。溴结构域(BRD) 染色质阅读器蛋白是组蛋白赖氨酸乙酰化的主要阅读器。尽管被认为是关键 癌症的表观遗传机制和新兴的“可药物靶点”,我们的理解存在很大差距 组蛋白乙酰赖氨酸和BRD之间存在的功能关系。此外, 关于BRD在BCa抗雌激素反应中的作用。我们之前已经描述了 在BCa和ETR的细胞模型中的表观基因组谱。我们发表的结果支持表观基因组范围内 雌激素反应元件的重编程与内分泌敏感性和ETR的获得有关。 通过一套完整而系统的具体目标,我们将检验BRD介导的假设 BCa的内分泌反应性。本项目将特别关注可能会影响 改进靶向治疗的潜力:鉴定特定的含溴结构域蛋白, 在癌症治疗中靶向增强细胞对他莫昔芬的反应, 在ET的早期和晚期,含BRD的蛋白质对转录可塑性的影响, 复发性转移性ER+乳腺癌的表观遗传学特征,以将全球 BRD的组蛋白结合活性。总的来说,这项工作将有助于我们对BCa的理解 表观遗传机制,并将有助于发现新的生物标志物的内分泌反应和 开发新的治疗干预模式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Seth E Frietze其他文献

Seth E Frietze的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Seth E Frietze', 18)}}的其他基金

Project 2: Bromodomains as Epigenetic Modulators of Endocrine Responsiveness in ER+ Breast Cancer
项目 2:溴结构域作为 ER 乳腺癌内分泌反应性的表观遗传调节剂
  • 批准号:
    10380072
  • 财政年份:
    2021
  • 资助金额:
    $ 37.21万
  • 项目类别:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
破译 ATAD2/B 组蛋白密码识别的分子机制
  • 批准号:
    10410677
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Understanding Ikaros molecular functions for targeted therapies of pre-B ALL
了解 Ikaros 分子功能用于前 B ALL 靶向治疗
  • 批准号:
    10433981
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Role of the transcription factor Ikaros in development of autoimmune disease
转录因子 Ikaros 在自身免疫性疾病发展中的作用
  • 批准号:
    10159202
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Role of the transcription factor Ikaros in development of autoimmune disease
转录因子 Ikaros 在自身免疫性疾病发展中的作用
  • 批准号:
    10408036
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
破译 ATAD2/B 组蛋白密码识别的分子机制
  • 批准号:
    9788498
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
破译 ATAD2/B 组蛋白密码识别的分子机制
  • 批准号:
    10005379
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
破译 ATAD2/B 组蛋白密码识别的分子机制
  • 批准号:
    10592912
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
破译 ATAD2/B 组蛋白密码识别的分子机制
  • 批准号:
    10452326
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:
Understanding Ikaros molecular functions for targeted therapies of pre-B ALL
了解 Ikaros 分子功能用于前 B ALL 靶向治疗
  • 批准号:
    9750657
  • 财政年份:
    2018
  • 资助金额:
    $ 37.21万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 37.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了